EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Limited efficacy of a therapeutic anti-CD40 monoclonal antibody to inhibit activated CD4 T cell autoimmunity in vitro

Chelsea Gootjes iD, Jaap Jan Zwaginga, Tatjana Nikolic, Bart O Roep iD

PLOS One · 12.06.2026 · 21 (6) · e0351131

DOI: 10.1371/journal.pone.0351131 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 12.06.2026. Verfasst von Chelsea Gootjes und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Section Immunomodulation and Regenerative Cell Therapy, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: CD40 Antigens, CD4-Positive T-Lymphocytes, Antibodies, Monoclonal, Autoimmunity. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stichting Diabetes Onderzoek Nederland, HORIZON EUROPE European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Iscalimab is a nondepleting anti-CD40 monoclonal antibody, expected to suppress immune responses by blocking the costimulation by antigen-presenting cells through CD40-CD40L ligation. This therapeutic antibody indeed inhibited proliferation of B lymphocytes and TNF production by dendritic cells and is being tested in clinical trials to treat B cell mediated autoimmune diseases. Since iscalimab showed limited clinical benefit and did not improve kidney and liver transplantation outcomes compared to standard tacrolimus treatment, we studied whether a biosimilar of iscalimab affects T cell responses in vitro. For this, we stimulated autoreactive effector and alloreactive naïve CD4 T cells in the presence of anti-CD40 antibody and measured the impact on cell proliferation. While we confirmed the capacity of iscalimab biosimilar antibody to bind to B cells and dendritic cells and to completely inhibit proliferating B cells, it showed limited to no efficacy to inhibit proliferation of diabetogenic beta-cell specific effector CD4 T cell clones. The CD40 blockade also did not affect the induction of proliferation of naïve alloreactive CD4 T cells, by dendritic cells. Based on our in vitro data pointing to minimal inhibition of T cells by CD40 blockade, we propose that iscalimab may not suffice to accomplish durable benefit as intervention strategy to treat type 1 diabetes or other T cell mediated diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD40 AntigensCD4-Positive T-LymphocytesAntibodies, MonoclonalAutoimmunityLymphocyte ActivationCell ProliferationDendritic CellsB-LymphocytesAnimalsHumans

Substanzen

CD40 AntigensAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Internal Medicine, Section Immunomodulation and Regenerative Cell Therapy, Leiden University Medical Center, Leiden, The Netherlands.

ORCID-Profile: Chelsea Gootjes, Bart O Roep

Förderung

  • Stichting Diabetes Onderzoek Nederland
  • HORIZON EUROPE European Research Council

Zitieren

APA

Gootjes, C., Zwaginga, J. J., Nikolic, T., & Roep, B. O. (2026). Limited efficacy of a therapeutic anti-CD40 monoclonal antibody to inhibit activated CD4 T cell autoimmunity in vitro. PLOS One, 21(6), e0351131. https://doi.org/10.1371/journal.pone.0351131

Vancouver

Gootjes C, Zwaginga JJ, Nikolic T, Roep BO. Limited efficacy of a therapeutic anti-CD40 monoclonal antibody to inhibit activated CD4 T cell autoimmunity in vitro. PLOS One. 2026;21(6):e0351131. doi:10.1371/journal.pone.0351131

BibTeX
@article{Gootjes2026,
  author = {Gootjes, Chelsea and Zwaginga, Jaap Jan and Nikolic, Tatjana and Roep, Bart O},
  title = {Limited efficacy of a therapeutic anti-CD40 monoclonal antibody to inhibit activated CD4 T cell autoimmunity in vitro},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {6},
  pages = {e0351131},
  doi = {10.1371/journal.pone.0351131}
}
Kostenlos starten →